REDWOOD CITY, Calif., Dec. 4 (Korea Bizwire) — Coherus BioSciences, Inc. (Nasdaq:CHRS), a late-stage clinical biologics platform company focused on the global biosimilar market, today announced that it has scheduled a conference call for Monday, December 15, 2014, at 1:30 p.m. PT / 4:30 p.m. ET to discuss its third quarter 2014 financial results and pipeline progress. Participating in the call will be Denny Lanfear, President and Chief Executive Officer, and Jean-Frederic Viret, Chief Financial Officer. Prepared remarks will be followed by a question and answer session.
Financial results will be released over the wire after market close on Monday, December 15, 2014 and posted on the Coherus website.
Conference Call Information:
When: December 15, 2014, 1:30 p.m. PT
Dial-in: 844-452-6826 (domestic) or 765-507-2587 (international)
Conference ID: 47041295
Please join the conference call at least 10 minutes early to register.
The webcast of the conference call will be available for replay through December 29, 2014.
About Coherus BioSciences, Inc.
Coherus is a late-stage clinical biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team’s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Coherus’ commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America.
Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com.
CONTACT: Jean-Frederic Viret, Ph.D.
Chief Financial Officer
Coherus BioSciences, Inc.
1 (800) 794-5434
Source: Coherus BioSciences via GLOBE NEWSWIRE